ClinicalTrials.gg
Active, not recruitingNCT06169527DUPILABUpdated Nov 19, 2026

A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab

An observational study in Atopic Dermatitis, sponsored by Sanofi. Active, not recruiting at 42 sites in France. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sanofi · Observational

How we know · 3 judgments

Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
303
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Dermatitis, Atopic by Sanofi — 5 open to participants now, 16 under way, 4 of them phase 3. Dermatitis, Atopic · Sanofi.

Enrollment
7th of 15
303 · median 266
Started
2023
with 9 others
Observational
15 of 43
3 open now
Primary completion
2028-07
later than 11 of 15 live
Registered
30th of 43
by date

Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 7th largest by enrollment of the 15 observational ones that give a count, is one of 10 that started in 2023, is one of 15 observational ones, reaches primary completion later than 11 of the 15 other live ones, and was the 30th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 43 studies in Dermatitis, Atopic by Sanofi are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Dermatitis, Atopic by Sanofi, or all of them as a file.
02

Study summary

This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to characterize real-world effectiveness, safety and use patterns of dupilumab in real world setting in France. Patients will be invited to participate if initiating treatment with dupilumab for AD according to French-specific prescribing information. The decision of initiation of the treatment is independent to the study's participation. The study will be conducted in approximately 50 centers in France to evaluate a representative sample of patients treated in France. At each participating site, all AD participants who receive an initial prescription for dupilumab will be invited to participate in this study, until the enrollment goal is achieved.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The population of interest for this study will be patients in France aged 6 years old or more with a diagnosis of AD either severe or moderate to severe (depending on age group) who initiate dupilumab in real world setting. The study will be conducted in real conditions of practice, dupilumab will be prescribed at the sole initiative of the participating physician irrespective of patient enrolment decision.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 6 years or older.
  • Initiating treatment with dupilumab for AD according to French-specific prescribing information (≥ 12 years old: moderate to severe AD versus 6-11 years old: severe AD). The decision of initiation of the treatment is independent to the study's participation.
  • Able to understand and complete study-related questionnaires.
  • Signed form. For participants \<18 years old, Informed consent form signed by the parent/legal guardian and participant's assent obtained.

Exclusion criteria

Exclusion Criteria:

  • Patients who have a to the drug according to the French-specific prescribing information label.
  • Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short , substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing, as per routine care, the schedule of visits and assessments.
  • Patients currently participating in any interventional clinical trial.
  • Patients previously treated with dupilumab.
  • Patients under tutorship or curatorship; patients under safeguard of justice or deprived of his/her liberty by an administrative or court decision.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
303 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants with AD treated with dupilumab

    Patients ≥6 years of age in whom dupilumab therapy was initiated to treat their AD according to French-specific prescribing information.

    Drug: Dupilumab

Interventions

  • Dupilumab cohort

    Also known as: SAR231893, Dupixent®

06

What researchers measure

Primary outcomes

  1. Demographic characteristics of participants who receive dupilumab for AD

    Including age, gender, educational level, socio-professional category

    Time frame: At baseline

  2. Weight characteristics of participants who receive dupilumab for AD

    Time frame: At baseline

  3. Height characteristics of participants who receive dupilumab for AD

    Time frame: At baseline

  4. Medical history characteristics of participants who receive dupilumab for AD

    including previous treatments for AD, relevant medical history, family history of atopy

    Time frame: At baseline

  5. Comorbidities and treatments change from baseline

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

  6. Atopic comorbidities and treatments change from baseline

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

  7. Change from baseline in lifestyle habits of participants who receive dupilumab for AD

    Including alcohol, tobacco, CBD and cannabis consumption

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable

  8. Change from baseline in dupilumab dose

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

  9. Change from baseline in dupilumab administration

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

  10. Change from baseline in dupilumab compliance with treatment

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

  11. Change from baseline in dupilumab temporary or permanent discontinuation

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

  12. Change from baseline in dupilumab treatment switch to another therapy

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

  13. Change from baseline in dupilumab treatment for concomitant AD treatments

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

  14. Change in patient's treatment satisfaction score using the Patient Global Assessment of Treatment Effect (PGATE)

    PGATE for patients ≥ 12 years of age: an internally developed and validated instrument allowing patients to rate their opinion and perceived treatment effect. Ratings are on a 5-point Likert scale from 1 being "Poor" and 5 being "Excellent".

    Time frame: At month 6, month 12, month 18, month 24, month 30, month 36

  15. Change in eczema severity using the Eczema Area and Severity Index (EASI)

    EASI is a validated measure used to assess severity and extent of AD at each body region by multiplying the lesions characteristics score x the body area score x multiplier. Four AD disease characteristics -erythema, thickness (induration, population, and oedema), scratching (excoriation), and lichenification - will each be assessed for severity by the observing physician, as follows: 0 = none, absent; 1=mild (just perceptible); 2=Moderate (obvious); 3=Severe. The area score ranges from 0 to 6 is determined as follows: 0= 0% (no active eczema in region); 1= 1-9%; 2= 10-29%; 3= 30-49%; 4= 50-69%; 5= 70-89%; 6= 90-100% (entire region affected by eczema). The multiplier is determined according to the region affected and the age of the patient: 0.1 or 0.2 for patients \< 8 years old (head/neck), 0.2 (upper limbs), 0.3 (trunk), 0.4 or 0.3 for patients \< 8 years old (lower limbs). A higher score means higher AD severity. Scores range from 0 (no disease) to 72 (maximal disease severity).

    Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

  16. Change in AD disease control using the Atopic Dermatitis Control Tool (ADCT)

    ADCT for patients aged ≥ 12 years of age: a validated, brief and easily scored tool consisting of six concise questions allowing to rate the different dimensions of patient-perceived AD control, to foster communication between patients and their physicians and help appropriate decision-making. The instrument includes 6 items, with a 7-day recall period: overall severity of symptoms, frequency of intense episodes of itching, severity of bother, frequency of sleep impact, severity of daily activities impact and severity of mood or emotions impact. Each item is rated on a 5-point Likert scale, ranging from 0 (none/ not at all/ no nights) to 4 (very severe/ everyday/ extremely/ every night); the total score ranges from 0 to 24, which is the summation of the responses to all the items. A total score of ≥7 points was derived as the threshold to identify patients "not in control", based on optimal sensitivity/ specificity values. The higher the score, the less AD is controlled.

    Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

  17. Change in itch assessment

    Itch assessment (Worst-Itch Numeric Rating Scale, WI-NRS) will be rated from 0 to 10 on average during the past 7 days (adult, pediatric and adolescent patients), completed by the observing physician after questioning of patient; 0 = no itch and 10 = the worst imaginable itch.

    Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

  18. Change in sleep disturbance NRS

    NRS sleep disturbance will be rated from 0 to 10 on average during the past 7 days (adult, pediatric and adolescent patients), completed by the observing physician after questioning of patient; 0 = "sleep not disturbed at all" (best possible sleep) and 10 = "sleep extremely disturbed (worst possible sleep)".

    Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

  19. Change in global patient's disease evaluation using the Patient Global Assessment of Disease Severity (PGADS)

    PGADS for patients ≥ 12 years of age: an internally developed and validated instrument allowing to the patients to rate their AD-related overall well-being. Patients will be asked: "Considering all the ways in which your eczema affects you, how well are you doing?" Response choices will be from 1 being "Poor" to 5 being "Excellent".

    Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

  20. Change in global patient's disease evaluation using the Caregiver Global Assessment of Disease (CGAD)

    CGAD for patients 6 to 11 years of age: an internally developed and validated instrument allowing to the caregivers to rate their child's AD-related overall well-being. Caregivers will be asked: "Considering all the way in which the eczema affects your child, how well is your child doing?". Response choices will be 1 being "Poor" to 5 being "Excellent".

    Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

  21. Change in Dermatology Life Quality Index (DLQI)

    DLQI for patients ≥ 16 years (or cDLQI for patients \< 16 at baseline) are 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life in adults and pediatrics, respectively. The format is a simple response (0 to 3 where 0 is "not at all" and 3 is "very much") to 10 items, which assess quality of life over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor quality of life. Patients 6-11 years old will be assisted for questionnaire completion. A cDLQI's cartoon version could be also used for patients from 6 to 11 years old. If a patient turns 16 years old during the study, they will switch to DLQI.

    Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

  22. Change in Dermatitis Family Impact Questionnaire (DFI)

    DFI is a 10-item, validated questionnaire assessing the impact of AD on the QoL of the parents/legal representatives and family members of affected children. The format is a simple response (0 to 3 where 0 is "not at all" and 3 is "very much") to 10 items, which assess Quality of Life (QoL) over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor QoL. It is designed to be completed by adults (aged 16 years or over) who have a child (up to and including the age of 15 years 11 months) in the family with atopic dermatitis.

    Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

  23. Change in European Quality of Life-5 Dimensions-3 level score (EQ-5D-3L)

    The EQ-5D-3L is completed by patients≥18 years old and by parent/legal representative of patients\<18 years old. It consists of 2 parts: * The EQ-5D descriptive system has five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 3 levels: no problems, some problems, and extreme problems. The patient selects the most appropriate statement in each of the five dimensions, resulting in a 1-digit number for each dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. * The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement. The scale is numbered 0 to 100. A higher value represents better health and a lower value represents worse health.

    Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36

  24. Change in Work Productivity and Activity Impairment Questionnaire, Atopic Dermatitis (WPAI-AD)

    WPAI-AD for adults and WPAI-CIQ-AD for adolescents is a questionnaire designed to assess the impact of AD on the patient's productivity. The WPAI-AD is the version of the original generic WPAI that is specific to AD. It is a 6-item, validated questionnaire to measure impairments in work and activities over a 7-day recall period. The WPAI-AD outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. If a patient turns 18 years old during the study, this one will switch to WPAI-AD.

    Time frame: At month 6, month 12, month 18, month 24, month 30, month 36

  25. Number of Adverse Events (AE)

    AEs for dupilumab and/or concomitant treatments will be collected throughout the study.

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

  26. Change from baseline in Drug Survival

    Drug survival is defined as the time from the start of treatment to the end or discontinuation of treatment with no changes. If a patient has multiple drug survival events for the same treatment, the longest drug survival will be used in the data summarization. The drug survival will be illustrated using a Kaplan-Meier plot.

    Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

07

Study locations

42 sites
  • Investigational Site Number: 2500041
    Amiens, 80054, France
  • Investigational Site Number: 2500037
    Angers, 49000, France
  • Investigational Site Number: 2500021
    Argenteuil, 95107, France
  • Investigational Site Number: 2500044
    Armentières, 59280, France
  • Investigational Site Number: 2500018
    Arras, 62000, France
  • Investigational Site Number: 2500011
    Ars-Laquenexy, 57530, France
  • Investigational Site Number: 2500023
    Avignon, 84000, France
  • Investigational Site Number: 2500001
    Besançon, 25000, France
  • Investigational Site Number: 2500003
    Bron, 69500, France
  • Investigational Site Number: 2500043
    Caen, 14033, France
  • Investigational Site Number: 2500050
    Chambéry, 73000, France
  • Investigational Site Number: 2500006
    Clermont-Ferrand, 63113, France
  • Investigational Site Number: 2500005
    Dijon, 21231, France
  • Investigational Site Number: 2500004
    Epagny Metz Tessy, 74370, France
  • Investigational Site Number: 2500039
    Fort-de-France, 97261, France
  • Investigational Site Number: 2500045
    La Tronche, 38700, France
  • Investigational Site Number: 2500019
    Le Havre, 76083, France
  • Investigational Site Number: 2500040
    Le Mans, 72037, France
  • Investigational Site Number: 2500038
    Les Sables-d'Olonne, 85100, France
  • Investigational Site Number: 2500048
    Levallois-Perret, 92300, France
  • Investigational Site Number: 2500032
    Lille, 59037, France
  • Investigational Site Number: 2500002
    Limoges, 87000, France
  • Investigational Site Number: 2500036
    Lorient, 56100, France
  • Investigational Site Number: 2500029
    Marseille, 13008, France
  • Investigational Site Number: 2500028
    Montpellier, 34090, France
  • Investigational Site Number: 2500024
    Nantes, 44093, France
  • Investigational Site Number: 2500025
    Nice, 06000, France
  • Investigational Site Number: 2500020
    Nice, 6300, France
  • Investigational Site Number: 2500016
    Pau, 64000, France
  • Investigational Site Number: 2500009
    Périgueux, 24019, France
  • Investigational Site Number: 2500042
    Poitiers, 86000, France
  • Investigational Site Number: 2500022
    Pontoise, 95300, France
  • Investigational Site Number: 2500014
    Romans-sur-Isère, 26102, France
  • Investigational Site Number: 2500008
    Rouen, 76031, France
  • Investigational Site Number: 2500015
    Saint-Germain-en-Laye, 78100, France
  • Investigational Site Number: 2500027
    Saint-Mandé, 94163, France
  • Investigational Site Number: 2500026
    Saint-Nazaire, 44606, France
  • Investigational Site Number: 2500035
    Saint-Pierre, 97410, France
  • Investigational Site Number: 2500013
    Saint-Pierre, 97448, France
  • Investigational Site Number: 2500012
    Toulouse, 31059, France
  • Investigational Site Number: 2500010
    Valence, 26000, France
  • Investigational Site Number: 2500031
    Vandœuvre-lès-Nancy, 54500, France
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jul 2028, 55 months after the start.

Of 74 industry-sponsored observational studies under Dermatitis, Atopic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 84. This study's planned 55 months is above that.

Counting every sponsor, half of 172 studies reached it within 47 months; a quarter within 17.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion May 2028 → Jul 2028 and completion May 2028 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Dec 13, 2023
StartActual
Nov 28, 2023
Primary completionEst.
Jul 5, 2028was May 2028
CompletionEst.
Jul 5, 2028was May 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 10, 2028→Jul 5, 2028
Nov 19, 2026
Study completion
May 10, 2028→Jul 5, 2028
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion May 10, 2028→Jul 5, 2028
    Study completion May 10, 2028→Jul 5, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06169527
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Nov 28, 2023
Primary completion
Jul 5, 2028 (estimated)
Completion
Jul 5, 2028 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion